INIS
patients
100%
heart failure
100%
peptides
80%
symptoms
80%
angiotensin
80%
capacity
60%
therapy
60%
quality of life
60%
receptors
60%
distance
60%
clinical trials
40%
comparative evaluations
40%
morbidity
40%
design
20%
levels
20%
cities
20%
inhibition
20%
death
20%
plasma
20%
concentration
20%
heart disease
20%
exercise
20%
enzyme inhibitors
20%
kansas
20%
Medicine and Dentistry
Heart Failure
100%
Ejection Fraction
80%
Drug Therapy
60%
Combination Therapy
60%
Amino Terminal Sequence
60%
Brain Natriuretic Peptide
60%
Inpatient
60%
Quality of Life
60%
Morbidity
40%
Angiotensin Receptor Antagonist
40%
Functional Status
40%
Cardiovascular System
40%
Enkephalinase Inhibitor
40%
Patient
40%
Enalapril
20%
ACE Inhibitor
20%
New York Heart Association Class
20%
Angiotensin Receptor
20%
Exercise
20%
Cardiomyopathy
20%
Valsartan
20%
Natriuretic Factor
20%
Neprilysin
20%
Plasma
20%
Amaurosis
20%
Pharmacology, Toxicology and Pharmaceutical Science
Heart Failure
100%
Valsartan/Sacubitril
80%
Symptom
80%
Randomized Clinical Trial
60%
Brain Natriuretic Peptide
60%
Clinical Trial
60%
Angiotensin Receptor Antagonist
40%
Functional Status
40%
Morbidity
40%
Peptide Hydrolase Inhibitor
40%
Placebo
40%
Dipeptidyl Carboxypeptidase Inhibitor
20%
Enalapril
20%
Angiotensin Receptor
20%
Membrane Metalloendopeptidase
20%
Death
20%
Heart Disease
20%
Natriuretic Factor
20%
Cardiomyopathy
20%
Valsartan
20%
Blindness
20%
Biochemistry, Genetics and Molecular Biology
Heart Ejection Fraction
80%
Natriuretic Peptide
80%
N-Terminus
60%
Angiotensin Receptor
60%
Neprilysin
60%
Life
60%
Morbidity
40%
Functional Status
40%
Angiotensin-Converting Enzyme
20%
Enzyme Inhibitor
20%
Exercise
20%
Association
20%